The 200,000 sq. ft. facility will manufacture elastomeric components. But, why the US? Williamson said, “the US has shown strong double-digit growth in biologics … and almost all are injectables, which will require components manufactured by Datwyler​.”

“The US remains the fasted growing regions of biologic and biosimilar developments​,” she added. “We would like to further strengthen our position here​.”

However, the company’s global footprint is also about to increase as it will roll out a new healthcare offering strategy.

Williams explained the three care programs will enable access to offerings in “an easy and intuitive way​.” The care programs include, “Bio Care, Pharma Care, and Med Care​.” Additional details on the programs will be released later this week.

“This is a huge strategic investment from Datwyler​,” concluded Williamson. “The largest in our company history​.”